RedHill Biopharma Ltd.RDHLNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank46
Year-over-Year Change
Year-over-year SG&A expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P46
Within normal range
Streak
1 qtr
Consecutive growthDecelerating
Average
8.21%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | -10.27% |
| Q4 2024 | 0.00% |
| Q3 2024 | -26.76% |
| Q2 2024 | 0.00% |
| Q1 2024 | -25.41% |
| Q4 2023 | 0.00% |
| Q3 2023 | -25.51% |
| Q2 2023 | -26.10% |
| Q1 2023 | -16.20% |
| Q4 2022 | -4.28% |
| Q3 2022 | -20.20% |
| Q2 2022 | -16.39% |
| Q1 2022 | 15.99% |
| Q4 2021 | -26.68% |
| Q3 2021 | -5.93% |
| Q2 2021 | 21.34% |
| Q1 2021 | -13.72% |
| Q4 2020 | 17.28% |
| Q3 2020 | 29.67% |
| Q2 2020 | 17.69% |
| Q1 2020 | 32.09% |
| Q4 2019 | 31.64% |
| Q3 2019 | 19.42% |
| Q2 2019 | 26.84% |
| Q1 2019 | 2.40% |
| Q4 2018 | 6.78% |
| Q3 2018 | -8.14% |
| Q2 2018 | 0.86% |
| Q1 2018 | -19.86% |
| Q4 2017 | -1.41% |
| Q3 2017 | 21.28% |
| Q2 2017 | 176.88% |
| Q1 2017 | 20.30% |
| Q4 2016 | 12.71% |
| Q3 2016 | 21.65% |
| Q2 2016 | -5.13% |
| Q1 2016 | -28.41% |
| Q4 2015 | 147.69% |
| Q3 2015 | -13.61% |